Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
This trial will evaluate the feasibility, toxicity, and efficacy of docetaxel/estramustine,
as in the adjuvant therapy of patients with high-risk prostate cancer after definitive local
therapy.